| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.43% | 1968.13% | 63.93% | 60.52% | 61.38% | 36.78% | 10.09% | 40.41% | 51.29% | 17.21% | 38.03% | 17.72% |
| Operating Margin | -3269.35% | -3007.66% | -177.26% | -412.38% | -415.45% | -752.64% | -708.02% | -406.16% | -346.89% | -574.86% | -369.72% | -278.04% |
| EBITDA Margin | -3265.60% | -3000.91% | -175.87% | -409.44% | -413.74% | -731.23% | -693.42% | — | -343.56% | -569.20% | -365.59% | -273.35% |
| Net Margin | -3209.75% | -2774.92% | -131.22% | -411.16% | -455.39% | -776.70% | -721.61% | -410.72% | -350.67% | -603.21% | -385.17% | -279.46% |
| Current Ratio | 1.99 | 0.92 | 2.73 | 1.32 | 4.13 | 1.55 | 4.59 | 1.66 | 5.17 | 17.00 | 2.48 | — |
| Quick Ratio | 1.99 | 0.43 | 1.74 | 0.84 | 3.72 | 1.11 | 4.10 | 1.57 | 5.03 | 16.82 | 2.41 | — |
| Debt / Equity | — | -0.18 | — | — | — | 0.87 | 0.00 | 0.76 | 0.28 | 0.15 | -0.18 | — |
| ROE | -272.78% | 162.38% | 184.43% | -1262.33% | -134.43% | -264.39% | -149.38% | -285.19% | -99.01% | -31.83% | 28.21% | — |
| ROA | -157.95% | -148.76% | -106.79% | -414.77% | -114.15% | -116.17% | -116.10% | -123.02% | -65.47% | -25.98% | -109.39% | — |
| Asset Turnover | 0.05 | 0.05 | 0.81 | 1.01 | 0.25 | 0.15 | 0.16 | 0.30 | 0.19 | 0.04 | 0.28 | — |
| Book Value / Share | 1.74 | -8.52 | -1.04 | 8.63 | 3.72 | 1.19 | 3.37 | 0.69 | 2.10 | 15.23 | -96.20 | — |
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.